• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Tivozanib

Tivozanib

Product ID T3585
Cas No. 475108-18-0
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $153.10 In stock
10 mg $236.90 In stock
25 mg $501.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Tivozanib is an anticancer chemotherapeutic and anti-angiogenic compound that inhibits VEGFR1/2/3, c-Kit, and PDGFR. Tivozanib is currently in clinical trials as a potential treatment for renal cell carcinoma. The antiangiogenic activity of tivozanib is exhibited by its ability to suppress development of choroidal neovascular (CNV) lesions and also to regress established CNV in animal models.

Product Info

Cas No.

475108-18-0

Purity

≥98%

Formula

C22H19ClN4O5

Formula Wt.

454.86

Chemical Name

1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1, 2-oxazol-3-yl)urea

IUPAC Name

1-[2-chloro-4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-3-(5-methyl-1, 2-oxazol-3-yl)urea

Synonym

AV-951

Appearance

Gray powder

Shipping and Storage

Store Temp

Ambient

Ship Temp

Ambient

Downloads

MSDS

T3585 MSDS PDF

Info Sheet

T3585 Info Sheet PDF

References

Cowey CL. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma. Drug Des Devel Ther. 2013 Jun 21;7:519-27. PMID: 23818763.

Hepgur M, Sadeghi S, Dorff TB, et al. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013;7:139-48. PMID: 23788831.

Kang S, Roh YJ, Kim IB. Antiangiogenic effects of tivozanib, an oral VEGF receptor tyrosine kinase inhibitor, on experimental choroidal neovascularization in mice. Exp Eye Res. 2013 Jul;112:125-33. PMID: 23701975.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • I4962

    Isoimperatorin

    Furocoumarin; COX-2 inhibitor.

    ≥98%
  • D3330

    Dihydrotanshinone

    Found in Salvia; fatty acid synthase and AChE i...

    ≥90%
  • A4805

    Amastatin Hydrochloride Hydrate

    Aminopeptidase inhibitor.

    ≥98%
  • T7033

    Trifluoperazine Dihydrochloride

    Phenothiazine; D1/2 and α1-adrenergic antagoni...

    ≥98%
  • M0126

    Magainin 2

    Antimicrobial peptide found in frogs, induces p...

    ≥95%
  • D3349

    Dimebon Dihydrochloride

    AMPK activator, L-type Ca2+ channel and NMDA, h...

    ≥98%
  • D1643

    Delta Sleep Inducing Peptide

    Peptide; GABA potentiator, NMDA negative allost...

    ≥95%
  • G4535

    Glimepiride

    Sulfonylurea; ATP-sensitive K+ channel blocker....

    ≥98%
  • T0095

    Baccatin III

    Diterpene found in Taxus, used to synthesize ta...

    ≥98%
  • I4800

    Imatinib free base

    Inhibitor of Abl, c-Kit, and PDGFR.

    ≥99%
  • T3185

    Thymidine

    Pyrimidine nucleoside base, pairs with adenosin...

    ≥98%
  • I0800

    IC-87114

    p110δ PI3K inhibitor.

    ≥98%
  • T1298

    TDZD-8

    GSK-3β inhibitor.

    ≥98%
  • L5767

    Loratadine

    Histamine H1 antagonist, FIASMA.

    ≥98%
  • J5237

    JNJ-26854165

    MDM2 inhibitor.

    ≥98%
  • I7155

    Isoindigo

    Potential AhR binding agent.

    ≥98%
  • L0250

    Laminin Peptide SIKVAV

    Laminin-derived hexapeptide.

    ≥98%
  • R0253

    Ranitidine Hydrochloride

    Histamine H2 inverse agonist.

    ≥98%
  • W317520

    WIN 55,212-2 Mesylate

    Non-selective cannabinoid receptor agonist.

    ≥98%
  • A980005

    AZ-5104

    Inhibitor of EGFR.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only